ADAP News and Press, Adaptimmune Therapeutics plc From 11/12/21

- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests that addition of AKT inhibitor (AKTi) during manufacture can remodel gene express...

Adaptimmune Therapeutics (ADAP -0.5%) announced that its ongoing SPEARHEAD-1 trial for afami-cel in advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) would meet the primary endpoint based on the overall response rate (ORR). The company is on track to report updated data ...

- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - - The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rat...

Image source: The Motley Fool. Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q3 2021 Earnings Call Nov 4, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Trans...

Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Conference Call November 4, 2021 08:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer John Lunger - Chief Patient Supply Officer Helen Tayton-Martin - Co-Founder and Chi...

Adaptimmune (NASDAQ:ADAP): Q3 GAAP EPS of -$0.05 beats by $0.21. Revenue of $1.2M (+0.8% Y/Y) beats by $0.26M. Press Release Financial Guidance: The Company believes that its existing cash, cash equivalents and marketable securities, together with the upfront and exclusivity payments under th...

- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - - SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tumors: overall response rate of 36%...

Adaptimmune (NASDAQ:ADAP) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $0.94M (-21.0% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downwa...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US mar...